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Fig. 1 Chemical struc-
ture of pentadeca-
(8Z,13Z)-dien-11-yn-2-
one.
Table 1 IC50 values of pentadeca-(8Z,13Z)-dien-11-yn-2-one and positive con-
trol on human cancer cell lines after 72 h of exposure.
Compound IC50 value (µM) ± SEM
Jurkat MCF-7 HL-60 MeWo
Dienynone 2.1 ± 0.6 2.5 ± 0.7 21.3 ± 0.8 28.6 ± 2.3
Positive controla 0.9 ± 0.2 3.4 ± 0.5 0.8 ± 0.3 2.6 ± 0.9
Note: Data (mean ± SEM) are from three experiments carried out in triplicate; a 5-Flu-
orouracil was the positive control for MCF-7 and HL-60; cisplatin was the positive con-
trol for Jurkat and MeWo
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Abstract
!
In the present study, a further investigation of the cytotoxic activ-
ity of an acetylenic constituent of Echinacea pallida roots, namely,
pentadeca-(8Z,13Z)-dien-11-yn-2-one, was performed, revealing
a concentration-dependent cytotoxicity on several human cancer
cell lines, including leukemia (Jurkat and HL-60), breast carcino-
ma (MCF-7), and melanoma (MeWo) cells. As part of its mecha-
nism of action, the ability of this constituent to arrest the cell
cycle in the G1 phase was demonstrated on HL-60 cells. Further-
more, a stability test of the target compound over 72 h was car-
ried out, indicating that the cytotoxic activity can be attributed
mainly to the genuine, not oxidized, molecule.
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Medicinally used Echinacea species (E. pallida, E. angustifolia, and
E. purpurea, family Asteraceae) are among the most widely used
medicinal plants, mainly for their immunomodulatory, anti-in-
flammatory and antioxidant properties [1,2]. Moreover, Echina-
cea preparations are often used by cancer patients, in addition
to classical antineoplastic therapy, because of their ability to in-
crease immune system activity [3,4].
n-Hexane extracts from the roots of the three above-mentioned
Echinacea species have demonstrated in vitro anticancer activity
on human cancer cell lines and E. pallida extracts have shown the
greatest potency [5]. Furthermore, a bioassay-guided fractiona-
tion study has indicated that polyacetylenes and polyenes, which
are present in high concentration in E. pallida lipophilic root ex-
tracts [6–8] but not detected in those from E. purpurea and E. an-
gustifolia [9], are responsible for this activity [10]. In particular,
pentadeca-(8Z,13Z)-dien-11-yn-2-one (l" Fig. 1) has been re-
vealed to be a potent cytotoxic compound that is able to induce
apoptotic cell death at low micromolar concentrations in human
cancer cell lines (pancreatic MIA PaCa-2 and colonic COLO320)
[10]. This compound has also been demonstrated to inhibit P-gly-
coprotein efflux activity [11] and to have a good potential for oral
bioavailability [10].
The present work focused on the evaluation of the cytotoxic ac-
tivity of pentadeca-(8Z,13Z)-dien-11-yn-2-one on different hu-
man cancer cell lines and the possible involvement of cell cycle
arrest in its mechanism of action. Moreover, a comparison of the
cytotoxic effects of the natural and the synthesized compound
was performed.Chicca A et al. Cytotoxic Activity and… Planta Med 2010; 76: 444–446The results showed that pentadeca-(8Z,13Z)-dien-11-yn-2-one
exerts concentration-dependent cytotoxic activity on all the
tested human cancer cell lines (leukemia Jurkat and HL-60, breast
carcinomaMCF-7 andmelanomaMeWo), as indicated by the IC50
values reported in l" Table 1. The 10-fold greater sensitivity of
Jurkat and MCF-7 cells compared with HL-60 and MeWo cells
may be due to the different drug-resistance properties of cell
lines or cell line subclones used in this study. A similar difference
was previously reported for this compound between pancreatic
Mia PaCa-2 (a particularly apoptotic-resistant line) and colonic
COLO320 cells [5,10]. In several cases, the cytotoxicity of penta-
deca-(8Z,13Z)-dien-11-yn-2-one was of the same order of mag-
nitude as that of anticancer drugs currently used in therapy, such
as doxorubicin on MCF-7 cells [12] and cisplatin on Jurkat cells
[13]. The anticancer drugs 5-fluorouracil and cisplatin were used
as internal positive controls and their IC50 values are reported in
l" Table 1. It is noteworthy that in a previous study, this com-
pound demonstrated no significant cytotoxicity up to 100 µM on
human non-cancer cells [10].
With regard to effects on the cell cycle, in HL-60 cells, pentadeca-
(8Z,13Z)-dien-11-yn-2-one induced arrest in the G1 phase after
72 h of exposure, as reported in l" Table 2: at 20 µM (IC50 value)
83% of the cell population was in the G1 phase, while at 40 µM
(2 × IC50 value) 90% of cells were in the G1 phase. Similar data
were obtained with the other cell lines (data not shown). These
results indicate that G1 cell cycle arrest is one of the main mech-
anisms responsible for the cytotoxic activity of pentadeca-
(8Z,13Z)-dien-11-yn-2-one; moreover, they strengthen the evi-
dence that such a mechanism plays an important role in the anti-
cancer activity of natural acetylenic compounds, as reported for
falcarinol [14,15], panaxydol [16], and other similar compounds
[17].
Due to the well-known difficulty in purifying this acetylenic
compound from E. pallida roots [6,7], whose extracts contain
many other constituents of similar polarity, and owing to the
need for higher amounts of this constituent for biological assays,
a total synthesis of this secondary metabolite was recently car-
ried out [18]. In the present study, the cytotoxic activity of both
natural (isolated and purified from E. pallida roots) and synthetic
Table 2 Cell cycle distribution of HL-60 cells after treatment with negative
control or pentadeca-(8Z,13Z)-dien-11-yn-2-one for 72 h.
Compound Percentage of HL-60 cells arrested in:
G1 phase S phase G2 phase
Negative
control
69.7 ± 1.9% 12.6 ± 2.3% 12.7 ± 1.2%
Dienynone
(20 µM)a
82.9 ± 1.3% 8.9 ± 0.8% 4.6 ± 1.6%
Dienynone
(40 µM)b
90.3 ± 1.1% 5.9 ± 1.1% 3.3 ± 1.0%
Note: Data (mean ± SEM) are from three experiments carried out in triplicate. a IC50
value; b 2×IC50 value
Fig. 2 Cytotoxic profile of natural and synthesized pentadeca-(8Z,13Z)-di-
en-11-yn-2-one on the Jurkat human leukemia cancer cell line after 72 h of
exposure.
Fig. 3 Stability study of pentadeca-(8Z,13Z)-dien-11-yn-2-one as moni-
tored by RP-HPLC‑DAD for 72 h.
445Letters
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ity
 o
f M
od
en
a.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.pentadeca-(8Z,13Z)-dien-11-yn-2-one was compared in order to
investigate whether the synthetic approach may affect the anti-
cancer activity of this molecule. The results showed no differ-
ences in cytotoxic activity between the natural and synthesized
compounds, which exhibited the same potency on the Jurkat cell
line (l" Fig. 2), thus confirming the accuracy of the total synthesis
of this secondary metabolite.
The results of the stability study of pentadeca-(8Z,13Z)-dien-11-
yn-2-one in the culture medium are shown in l" Fig. 3. As de-
scribed in the literature [6,19], the oxidation of the authentic
compounds isolated from E. pallida roots proceeds via an inter-
mediate hydroperoxide, which is then reduced to the corre-
sponding alcohol. The results of the present study indicated that
the oxidation kinetics of pentadeca-(8Z,13Z)-dien-11-yn-2-one
is quite slow, since the area of the hydroperoxide intermediate
was about 25% after 72 h of exposure. The final product of the ox-
idation process, i.e. the hydroxylated derivative, was not ob-
served in the HPLC after 72 h of exposure. Considering that dur-
ing the first 24 h of exposure, the area of the hydroperoxide inter-
mediate is below 15%, the observed cytotoxic activity can be at-
tributed mainly to the genuine, not oxidized, compound. More
detailed investigations of the oxidation kinetics of authentic
polyacetylenes and polyenes isolated from E. pallida roots are
currently in progress.
In conclusion, the cytotoxic activity of pentadeca-(8Z,13Z)-dien-
11-yn-2-one against several human cancer cell lines has been
demonstrated, and the arrest of the cell cycle in the G1 phase
has been shown to be involved in its mechanism of action. Fur-
ther studies are in progress to elucidate possible cellular targets
(e.g., COX or LOX isoforms, cannabinoid or PPAR receptors, his-
tone deacetylase) and molecular pathways (as specific apoptotic
molecules) involved in the cytotoxic activity of this secondary
metabolite. Possible synergism with chemotherapeutic drugs is
under investigation as well.
Materials and Methods
!
Extraction and purification of pentadeca-(8Z,13Z)-dien-11-yn-2-
one from E. pallida roots was carried out as previously described
[6,7]. Synthesis of the compound was performed in agreement
with the literature [18]. The UV, IR, NMR, and MS data of the iso-
lated and synthesized compoundsmatchedwell with those in the
literature [6,18]. The degree of purity of the tested compound
was 98% as determined by RP-HPLC [7]. Considering the well-
known low chemical stability of E. pallida polyacetylenes and
polyenes [6], DMSO stock solutions of pentadeca-(8Z,13Z)-dien-
11-yn-2-one were stored at low temperature (− 80°C), protectedfrom light and kept under argon atmosphere to prevent any
chemical oxidation until required for the biological assays. Under
these storage conditions, the compound was found to be stable.
To check the stability of the tested compound under the applied
experimental conditions, a stability study was performed by pre-
paring a 100mM solution of pentadeca-(8Z,13Z)-dien-11-yn-2-
one in DMSO, whichwas further diluted to 100 µM concentration
with the culture medium. The resulting solution was incubated
for a set interval at 37°C and sampled at fixed time intervals for
the RP-HPLC‑DAD analysis [7].
All cell lines were obtained from the American Type Culture Col-
lection (ATCC) and cultured under the following conditions:
RPMI 1640 medium supplemented with L-glutamine (2mM),
10% fetal bovine serum, 50 IU/mL penicillin, and 50 µg/mL strep-
tomycin (Sigma-Aldrich). Cells were maintained at 37°C in a hu-
midified incubator under 5% CO2.
Cell viability was assessed using the cell proliferation reagent
WST-1 (Roche) as previously described [10].
Cell cycle analysis by flow cytometry was performed as previ-
ously described [20]. Briefly, 106 cells were plated in a 100-mmChicca A et al. Cytotoxic Activity and… Planta Med 2010; 76: 444–446
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l.culture dish and incubated for 48–72 h. Then, cells were fixed
with 90% ethanol and incubatedwith a staining solution contain-
ing RNase A (30 µg/mL) and propidium iodide (50 µg/mL) in
phosphate-citrate buffer (pH 7.2). Cellular DNA content was ana-
lyzed by flow cytometry using a Becton Dickinson laser-based
flow cytometer. At least 20000 cells were used for each analysis.
Differences among compound treatments were evaluated by the
one-way ANOVA test followed by the Newman-Keuls post-test. A
p value ≤ 0.05 was considered to be significant.
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